Celgene $4.5 Billion Notes Offering
2/20/2018

Davis Polk advised the joint book-running managers and representatives of the several underwriters on an SEC-registered offering by Celgene Corporation of $500 million aggregate principal amount of 2.875% senior notes due 2021, $1 billion aggregate principal amount of 3.250% senior notes due 2023, $1.5 billion aggregate principal amount of 3.900% senior notes due 2028 and $1.5 billion aggregate principal amount of 4.550% senior notes due 2048. Celgene intends to use the net proceeds from the offering to finance a portion of its acquisition of Juno Therapeutics, Inc.

Headquartered in Summit, New Jersey, Celgene Corporation is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases.

The Davis Polk corporate team included partner Richard D. Truesdell Jr. and associates Joseph S. Payne, Jaryn S. Fields and Jamie Kurtz. The intellectual property and technology team included associates Bonnie Chen and Soo Lim. The tax team included partner Neil Barr and associates Joshua J. Micelotta and Christina L. Tacoronti. All members of the Davis Polk team are based in the New York office.